Default company panoramic image

Odyssey Molecular

Providing the next generation of analytical epigenomic instruments based on single molecule nanofluidic technology.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Ithaca, NY, USA
  • Currency USD
  • Website

Company Summary

Odyssey Molecular is a start-up company, formed to provide the next generation of analytical epigenomic equipment to medical researchers, diagnostic labs, drug developers, and developers of stem cell therapies. The company will design and develop instruments for epigenomic testing based on single-molecule analytics. Odyssey's competitive advantage results from its unique abilities to analyze multiple epigenomic variables simultaneously.


  • Default avatar
    Harold Craighead

    Dr. Craighead holds the Charles Lake Jr. chaired professorship in the Applied and Engineering Physics Department at Cornell University. Harold is a member of the National Academy of Engineering and a leader in single molecule analysis and fluidics. Prior to Odyssey Molecular, Harold was co-founder of Pacific Biosciences, a biotech company that is producing high throughput DNA sequencing equipment.

  • Default avatar
    Paul Soloway

    Dr. Soloway is a professor in the Division of Nutritional Sciences at Cornell University. Paul is a recognized expert in molecular biology and epigenomics, with a unique research background studying the mechanisms controlling chromosomal placement of epigenetic modifications. He received his PhD in Molecular Biology from Princeton University.

  • Default avatar
    Stephen Levy

    Dr. Levy is an assistant professor in the Physics Department of Binghamton University. His research involves optical and electrical investigations of individual nucleic acid molecules in nanofluidic structures. He received his PhD in Physics from the University of California at Santa Barbara.